FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021230488> ?p ?o ?g. }

• W2021230488 endingPage "43" @default.
• W2021230488 startingPage "31" @default.
• W2021230488 abstract "Objective The objective of this multicenter, international study was to evaluate safety and tolerability of paliperidone extended-release (ER) tablets in elderly (age ≥65 years) patients with schizophrenia. The authors conducted a 6-week, double-blind, randomized, placebo-controlled, optional 24-week open-label extension study. Interventions consisted of flexible, once-daily doses of paliperidone ER (3–12 mg/day; 6-mg starting dose, adjusted in 3-mg dose increments) or placebo (2:1) during double-blind treatment and paliperidone ER only during open-label treatment. Measurements included adverse events, laboratory tests, physical examinations, 12-lead electrocardiograms, movement disorder rating scales, Positive and Negative Syndrome Scale, and Clinical Global Impression scale. The study was not powered to show statistical differences. Results Patients (N = 114) were predominantly female (73%); mean age was 70 years (double-blind phase). Concomitant disease presence was consistent with that of an older population. During the double-blind phase, discontinuation rates resulting from adverse events were similar between groups (paliperidone ER: 7%, placebo: 8%) as were incidences of treatment-emergent adverse events (paliperidone ER: 67%, placebo: 71%). Serious adverse events occurred in 3% of the paliperidone ER- and 8% of the placebo-treated patients. Elevated prolactin levels occurred in approximately one half of patients. No prolactin- or glucose treatment-related adverse events or noteworthy mean changes in body weight (0 kg [standard deviation: 2.1] and 0 kg [standard deviation: 2.3] for paliperidone ER and placebo, respectively) were observed. Safety and tolerability results in the extension were consistent with the shorter-term results. Efficacy measures did not show consistent statistical improvement between treatment groups. Conclusion Paliperidone ER (3–12 mg/day) treatment over a 30-week period was generally well-tolerated and may improve symptom severity in elderly patients with schizophrenia. The objective of this multicenter, international study was to evaluate safety and tolerability of paliperidone extended-release (ER) tablets in elderly (age ≥65 years) patients with schizophrenia. The authors conducted a 6-week, double-blind, randomized, placebo-controlled, optional 24-week open-label extension study. Interventions consisted of flexible, once-daily doses of paliperidone ER (3–12 mg/day; 6-mg starting dose, adjusted in 3-mg dose increments) or placebo (2:1) during double-blind treatment and paliperidone ER only during open-label treatment. Measurements included adverse events, laboratory tests, physical examinations, 12-lead electrocardiograms, movement disorder rating scales, Positive and Negative Syndrome Scale, and Clinical Global Impression scale. The study was not powered to show statistical differences. Patients (N = 114) were predominantly female (73%); mean age was 70 years (double-blind phase). Concomitant disease presence was consistent with that of an older population. During the double-blind phase, discontinuation rates resulting from adverse events were similar between groups (paliperidone ER: 7%, placebo: 8%) as were incidences of treatment-emergent adverse events (paliperidone ER: 67%, placebo: 71%). Serious adverse events occurred in 3% of the paliperidone ER- and 8% of the placebo-treated patients. Elevated prolactin levels occurred in approximately one half of patients. No prolactin- or glucose treatment-related adverse events or noteworthy mean changes in body weight (0 kg [standard deviation: 2.1] and 0 kg [standard deviation: 2.3] for paliperidone ER and placebo, respectively) were observed. Safety and tolerability results in the extension were consistent with the shorter-term results. Efficacy measures did not show consistent statistical improvement between treatment groups. Paliperidone ER (3–12 mg/day) treatment over a 30-week period was generally well-tolerated and may improve symptom severity in elderly patients with schizophrenia." @default.
• W2021230488 created "2016-06-24" @default.
• W2021230488 creator A5022689860 @default.
• W2021230488 creator A5035733086 @default.
• W2021230488 creator A5037622152 @default.
• W2021230488 creator A5044744410 @default.
• W2021230488 creator A5085006417 @default.
• W2021230488 creator A5085673205 @default.
• W2021230488 creator A5091766408 @default.
• W2021230488 date "2008-01-01" @default.
• W2021230488 modified "2023-09-26" @default.
• W2021230488 title "Safety and Tolerability of Oral Paliperidone Extended-Release Tablets in Elderly Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Study With Six-Month Open-Label Extension" @default.
• W2021230488 cites W1965027105 @default.
• W2021230488 cites W1980621268 @default.
• W2021230488 cites W1999689270 @default.
• W2021230488 cites W2001701208 @default.
• W2021230488 cites W2020615571 @default.
• W2021230488 cites W2073712495 @default.
• W2021230488 cites W2077138902 @default.
• W2021230488 cites W2079999567 @default.
• W2021230488 cites W2092841720 @default.
• W2021230488 cites W2120988652 @default.
• W2021230488 cites W2131658797 @default.
• W2021230488 cites W2137748078 @default.
• W2021230488 cites W2138785055 @default.
• W2021230488 cites W2140606211 @default.
• W2021230488 cites W2148347826 @default.
• W2021230488 cites W2162570691 @default.
• W2021230488 cites W2165379748 @default.
• W2021230488 cites W2321996472 @default.
• W2021230488 cites W2406749581 @default.
• W2021230488 cites W3049811 @default.
• W2021230488 cites W4244847179 @default.
• W2021230488 doi "https://doi.org/10.1097/jgp.0b013e31815a3e7a" @default.
• W2021230488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18165460" @default.
• W2021230488 hasPublicationYear "2008" @default.
• W2021230488 type Work @default.
• W2021230488 sameAs 2021230488 @default.
• W2021230488 citedByCount "84" @default.
• W2021230488 countsByYear W20212304882012 @default.
• W2021230488 countsByYear W20212304882013 @default.
• W2021230488 countsByYear W20212304882014 @default.
• W2021230488 countsByYear W20212304882015 @default.
• W2021230488 countsByYear W20212304882016 @default.
• W2021230488 countsByYear W20212304882017 @default.
• W2021230488 countsByYear W20212304882018 @default.
• W2021230488 countsByYear W20212304882019 @default.
• W2021230488 countsByYear W20212304882020 @default.
• W2021230488 countsByYear W20212304882021 @default.
• W2021230488 countsByYear W20212304882022 @default.
• W2021230488 countsByYear W20212304882023 @default.
• W2021230488 crossrefType "journal-article" @default.
• W2021230488 hasAuthorship W2021230488A5022689860 @default.
• W2021230488 hasAuthorship W2021230488A5035733086 @default.
• W2021230488 hasAuthorship W2021230488A5037622152 @default.
• W2021230488 hasAuthorship W2021230488A5044744410 @default.
• W2021230488 hasAuthorship W2021230488A5085006417 @default.
• W2021230488 hasAuthorship W2021230488A5085673205 @default.
• W2021230488 hasAuthorship W2021230488A5091766408 @default.
• W2021230488 hasConcept C118552586 @default.
• W2021230488 hasConcept C126322002 @default.
• W2021230488 hasConcept C142724271 @default.
• W2021230488 hasConcept C197934379 @default.
• W2021230488 hasConcept C204787440 @default.
• W2021230488 hasConcept C27081682 @default.
• W2021230488 hasConcept C2776412080 @default.
• W2021230488 hasConcept C2777126507 @default.
• W2021230488 hasConcept C2778375690 @default.
• W2021230488 hasConcept C2778715236 @default.
• W2021230488 hasConcept C2779727114 @default.
• W2021230488 hasConcept C2780135775 @default.
• W2021230488 hasConcept C2780494398 @default.
• W2021230488 hasConcept C2908647359 @default.
• W2021230488 hasConcept C2908997079 @default.
• W2021230488 hasConcept C42219234 @default.
• W2021230488 hasConcept C71924100 @default.
• W2021230488 hasConcept C99454951 @default.
• W2021230488 hasConceptScore W2021230488C118552586 @default.
• W2021230488 hasConceptScore W2021230488C126322002 @default.
• W2021230488 hasConceptScore W2021230488C142724271 @default.
• W2021230488 hasConceptScore W2021230488C197934379 @default.
• W2021230488 hasConceptScore W2021230488C204787440 @default.
• W2021230488 hasConceptScore W2021230488C27081682 @default.
• W2021230488 hasConceptScore W2021230488C2776412080 @default.
• W2021230488 hasConceptScore W2021230488C2777126507 @default.
• W2021230488 hasConceptScore W2021230488C2778375690 @default.
• W2021230488 hasConceptScore W2021230488C2778715236 @default.
• W2021230488 hasConceptScore W2021230488C2779727114 @default.
• W2021230488 hasConceptScore W2021230488C2780135775 @default.
• W2021230488 hasConceptScore W2021230488C2780494398 @default.
• W2021230488 hasConceptScore W2021230488C2908647359 @default.
• W2021230488 hasConceptScore W2021230488C2908997079 @default.
• W2021230488 hasConceptScore W2021230488C42219234 @default.
• W2021230488 hasConceptScore W2021230488C71924100 @default.
• W2021230488 hasConceptScore W2021230488C99454951 @default.
• W2021230488 hasIssue "1" @default.
• W2021230488 hasLocation W20212304881 @default.
• W2021230488 hasLocation W20212304882 @default.

• next